Update: Cure strategy remains the focus; data in 2015
FY14 financial results provided the first opportunity for Bionor’s new CEO David Solomon to affirm his commitment to the strategy to develop lead therapeutic vaccine Vacc-4x towards a functional HIV cure. The near-term priority remains the ongoing REDUC ‘Kick and Kill’ Phase II trial, with data expected during 2015, which is a key component of this. In addition, other opportunities for Vacc-4x, including in elite responders and as part of combination therapy continue to be explored. Our valuation is slightly increased to NOK988m with rolling forwards and updated net cash.Solon Eiendom is a biotechnology company. Co.'s focus is the research and development of peptide based vaccines against viral diseases, primarily human immunodeficiency virus (HIV). As of Dec 31 2013, Co.'s clinical development pipeline comprised of two vaccine candidates for the treatment of HIV, Vacc-4X and Vacc-C5. Vacc-4X is being investigated in two phases II trials in collaboration with Celgene Inc.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.